| Identification | Back Directory | [Name]
EL-102 | [CAS]
1233948-61-2 | [Synonyms]
EL-102
EL-102; EL 102
Benzenesulfonamide, N-[5-(5-cyano-3-thienyl)-2-methylphenyl]-4-methoxy-
N-[5-(5-cyano-thiophen-3-yl)-2-methyl-phenyl]-4-methoxy-benzenesulfonamide | [Molecular Formula]
C19H16N2O3S2 | [MOL File]
1233948-61-2.mol | [Molecular Weight]
384.47 |
| Chemical Properties | Back Directory | [Boiling point ]
548.1±60.0 °C(Predicted) | [density ]
1.40±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:36.0(Max Conc. mg/mL);93.64(Max Conc. mM) | [form ]
Solid | [pka]
8.14±0.10(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis, inhibits tubulin polymerisation and shows activities against prostate cancer. EL-102 can be used for the research of cancer[1]. | [in vivo]
EL-102 (12 and 15 mg/kg; p.o. 5-day on and 2-day off, from 13 to 37 days after tumour transplantation) potentiates effects of docetaxel in vivo[1]. | Animal Model: | Nude mice with CWR22 xenografts[1] | | Dosage: | 12 and 15 mg/kg | | Administration: | Oral gavage; 12 and 15 mg/kg 5-day on and 2-day off; from 13 to 37 days after tumour transplantation | | Result: | Showed no effect on tumor growth, but enhanced the effect of docetaxel on tumor . |
| [storage]
Store at -20°C | [References]
[1] A P Toner et al. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivoactivity against prostate cancer and circumvents MDR1 resistance. Br J Cancer, 2013 Oct 15, 109(8): 2131-2141. DOI:10.1038/bjc.2013.537 |
|
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
|